Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly) have been central to the treatment of advanced disease, the market is set to witness a substantial change within the next 10 years driven by the 2020 approval of Tecentriq (Roche / Genentech) plus bevacizumab, the FDA approval of Imfinzi plus Imjudo (AstraZeneca) and the anticipated entry of novel emerging immune checkpoint inhibitor-based combinations. The anticipated uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma market, where identified unmet needs remain to offer further opportunities for effective therapy development.

Questions answered

  • What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?
  • What is the size of market-relevant drug-treatable populations, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts’ insights on key existing and emerging agents?
  • What are the key factors driving or constraining market growth?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists.

Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech, AstraZeneca.

Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda, Imfinzi, Imjudo.

Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and Phase II products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Key updates
        • Q4 2022
          • December 2022
        • Q3 2022
          • August 2022
        • Q2 2022
          • June 2022
          • May 2022
          • April 2022
        • Q1 2022
          • March 2022
          • February 2022
          • January 2022
      • Market outlook
        • Key findings
          • Market share of drug classes for hepatocellular carcinoma: 2021
          • Market share of drug classes for hepatocellular carcinoma: 2031
          • Drug-treatable population share and major-market sales share in hepatocellular carcinoma: 2021
          • Drug-treatable population share and major-market sales share in hepatocellular carcinoma: 2031
          • Current therapies with sales potential in hepatocellular carcinoma: population positioning
          • Emerging therapies with sales potential in hepatocellular carcinoma: population positioning
          • Hepatocellular carcinoma SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for hepatocellular carcinoma?
          • What factors are constraining the market for hepatocellular carcinoma?
          • Major-market sales for hepatocellular carcinoma by drug-treatable population: 2021-2031
          • Major-market sales of immune checkpoint inhibitors for hepatocellular carcinoma: 2021-2031
          • Major-market sales of angiogenesis inhibitors for hepatocellular Carcinoma: 2021-2031
        • Segment-specific trends
          • Patient-share dynamics of therapies for early-stage hepatocellular carcinoma in the United States: 2021-2031
          • Patient-share dynamics of therapies in first-line intermediate-stage hepatocellular carcinoma in the United States: 2021-2031
          • Patient-share dynamics of therapies in second-line intermediate-stage hepatocellular carcinoma in the United States: 2021-2031
          • Patient-share dynamics of therapies in first-line advanced-stage hepatocellular carcinoma in the United States: 2021-2031
          • Patient-share dynamics of therapies in second-line advanced-stage hepatocellular carcinoma in the United States: 2021-2031
      • Forecast
        • Market forecast downloads
        • Market forecast assumptions
        • Market forecast dashboard
      • Etiology and pathophysiology
        • Disease overview
          • Etiology
            • Key risk factors associated with the development of hepatocellular carcinoma
          • Disease pathophysiology
            • Liver anatomy and tumorigenesis
            • Hepatocellular carcinoma pathogenesis
          • Staging and classification
            • Barcelona Clinic Liver Cancer staging criteria
            • TNM-AJCC staging system
            • TNM-LCSGJ staging system
            • Child-Pugh score
          • Key pathways and drug targets
            • Drug targets and potential therapies for hepatocellular carcinoma
            • Drug targets for hepatocellular carcinoma
            • Biology of immune checkpoint inhibitors and modulators
        • Epidemiology
          • Key findings
            • Epidemiology populations
              • Disease definition
              • Methods
              • Sources used for diagnosed incidence of hepatocellular carcinoma
              • Diagnosed incident cases of hepatocellular carcinoma: 2021-2031
              • Disease definition
              • Methods
              • Sources used for stage distribution of hepatocellular carcinoma
              • Diagnosed incident cases of hepatocellular carcinoma by stage distribution: 2021-2031
              • Definition
              • Methods
              • Sources used for recurrent incidence of hepatocellular carcinoma
              • Recurrent incident cases of hepatocellular carcinoma: 2021-2031
              • Hepatocellular carcinoma patient flow
              • Drug-treatable cases: 2021-2031
              • Drug-treated cases: 2021-2031
          • Current treatment
            • Key findings
              • Treatment goals
                • Key endpoints used in clinical trials for hepatocellular carcinoma
              • Key current therapies
                • Overview
                • Mechanism of action of key current drug classes used for hepatocellular carcinoma
                • Current treatments used for hepatocellular carcinoma
                • Market events impacting the use of key current therapies for hepatocellular carcinoma
                • Key results from select clinical trials investigating Nexavar for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Nexavar
                • Key ongoing clinical trials of Nexavar in the treatment of hepatocellular carcinoma
                • Expert insight: sorafenib
                • Key results from select clinical trials investigating Stivarga for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Stivarga
                • Key ongoing clinical trials of Stivarga in the treatment of hepatocellular carcinoma
                • Expert insight: Stivarga
                • Key results from select clinical trials investigating Lenvima for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Lenvima
                • Key ongoing clinical trials of Lenvima in the treatment of hepatocellular carcinoma
                • Expert insight: Lenvima
                • Key results from select clinical trials investigating Cabometyx for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Cabometyx
                • Key ongoing clinical trials of Cabometyx in the treatment of hepatocellular carcinoma
                • Expert insight: Cabometyx
                • Key results from select clinical trials investigating Cyramza for the treatment of hepatocellular carcinoma
                • Ongoing clinical development program for Cyramza
                • Expert insight: Cyramza
                • Key results from select clinical trials investigating Opdivo (with or without Yervoy) for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Opdivo (with or without Yervoy)
                • Key ongoing clinical trials of Opdivo (with or without Yervoy) in the treatment of hepatocellular carcinoma
                • Expert insight: Opdivo (with or without Yervoy)
                • Key results from select clinical trials investigating Keytruda for the treatment of hepatocellular carcinoma
                • Ongoing clinical development of Keytruda
                • Key ongoing clinical trials of Keytruda in the treatment of hepatocellular carcinoma
                • Expert insight: Keytruda
                • Key results from select clinical trials investigating Tecentriq for the treatment of hepatocellular carcinoma
                • Ongoing clinical development program for Tecentriq
                • Key ongoing clinical trials of Tecentriq in the treatment of hepatocellular carcinoma
                • Expert insight: Tecentriq
                • Key results from select clinical trials investigating Imfinzi (with and without Imjudo) for the treatment of hepatocellular carcinoma
                • Ongoing clinical development program for Imfinzi (with and without Imjudo)
                • Key ongoing clinical trials of Imfinzi (with and without Imjudo) in the treatment of hepatocellular carcinoma
                • Expert insight: Imfinzi (with and without Imjudo)
              • Medical practice
                • u200bEarly-stage hepatocellular carcinoma
                • Intermediate-stage hepatocellular carcinoma
                • Advanced-stage hepatocellular carcinoma
                • Patient characteristics influencing drug selection in hepatocellular carcinoma
                • Treatment decision tree for hepatocellular carcinoma: United States
                • Treatment decision tree for hepatocellular carcinoma: Europe
                • Treatment decision tree for hepatocellular carcinoma: Japan
            • Unmet need overview
              • Current and future attainment of unmet needs in hepatocellular carcinoma
              • Top unmet needs in hepatocellular carcinoma: current and future attainment
              • Expert insight: unmet need in hepatocellular carcinoma
            • Drug Pipeline
              • Pipeline
              • Regulatory Milestones
              • Indication Comparison
            • Emerging therapies
              • Key findings
                • Key emerging therapies
                  • Key therapies in development for hepatocellular carcinoma
                  • Estimated market authorization dates of key emerging therapies for the treatment of hepatocellular carcinoma
                  • Key results from select clinical trials investigating Tislelizumab for the treatment of hepatocellular carcinoma
                  • Key ongoing clinical trials of Tislelizumab in the treatment of hepatocellular carcinoma
                  • Analysis of the clinical development program for Tislelizumab
                  • Expert insight: tislelizumab
                  • Expectations for market authorization and sales opportunity of Tislelizumab in hepatocellular carcinoma
                  • Key results from select clinical trials investigating camrelizumab plus rivoceranib for the treatment of hepatocellular carcinoma
                  • Key ongoing clinical trials of camrelizumab plus rivoceranib in the treatment of hepatocellular carcinoma
                  • Analysis of the clinical development program for camrelizumab plus rivoceranib
                  • Expert insight: camrelizumab plus rivoceranib
                  • Expectations for market authorization and sales opportunity of camrelizumab plus rivoceranib in hepatocellular carcinoma
                  • Key results from select clinical trials investigating nofazinlimab for the treatment of hepatocellular carcinoma
                  • Key ongoing clinical trials of nofazinlimab in the treatment of hepatocellular carcinoma
                  • Analysis of the clinical development program for nofazinlimab
                  • Expectations for market authorization and sales opportunity of nofazinlimab in hepatocellular carcinoma
                  • Key ongoing clinical trials of toripalimab in the treatment of hepatocellular carcinoma
                  • Analysis of the clinical development program for toripalimab
                  • Expectations for market authorization and sales opportunity of toripalimab in hepatocellular carcinoma
                  • Key results from select clinical trials investigating namodenoson for the treatment of hepatocellular carcinoma
                  • Analysis of the clinical development program for namodenoson
                  • Key ongoing clinical trials of namodenoson in the treatment of hepatocellular carcinoma
                  • Expectations for market authorization and sales opportunity of namodenoson in hepatocellular carcinoma
                • Early-phase pipeline analysis
                  • Select compounds in early-phase development for hepatocellular carcinoma
              • Access & reimbursement overview
                • Region-specific reimbursement practices
                  • Key market access considerations in hepatocellular carcinoma: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in hepatocellular carcinoma: EU5
                  • General reimbursement environment: EU5
                  • Key market access considerations in hepatocellular carcinoma: Japan
                  • General reimbursement environment: Japan
              • Appendix
                • Abbreviations
                • Hepatocellular carcinoma bibliography

            Login to access report

            launch Related Market Assessment Reports